The pharmaceutical company’s payment will also settle allegations that it distributed Levothroid, used to treat hypothyroidism, without FDA approval and illegally marketed drug Celexa for unapproved treatment of children and adolescents, according to the report.
Forest Pharmaceuticals has also agreed to settle pending False Claim allegations that false claims were submitted to federal healthcare programs for Levothroid, Celexa and Lexapro, according to the report.
The FDA sent a letter in 2003 to Forest Pharmaceuticals, warning the company to cease distribution of the unapproved Levothroid after the company decided not to comply with the FDA’s distribution phase-down plan. After the letter was received, Forest Pharmaceuticals continued to work its St. Louis distribution center overtime until 1 a.m. to continue shipping as much of Levothroid as possible, according to the report.
Read the Business Courier report about the Forest Pharmaceutical settlement.
Read other coverage about settlements in healthcare fraud:
– Massachusett’s Clinical Science Laboratory to Pay $525K to Settle Medicaid Fraud Allegations
– Santa Monica’s Saint John’s Health Center to Pay $5.25M Settlement in Fraud Case
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.